No takes yet. Share an insight, caveat, or question.
Annual lesion load quantification correlates with monthly disease activity, supporting its use as a surrogate marker of disease evolution in MS phase III treatment trials.
Molyneux et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: